Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Gilead Sciences reports progress on Quad clinical trial programme

Gilead Sciences reports progress on Quad clinical trial programme

15th September 2010

Gilead Sciences has provided an update on the "rapid progress" it is making on the clinical development of its Quad treatment regimen for HIV patients.

The pharmaceutical company has fully enrolled a phase III study comparing the efficacy of the treatment with Atripla, while another trial comparing it to a protease-based regimen has now been closed for screening.

Quad is an investigational fixed-dose therapy which combines elvitegravir, cobicistat and Truvada (emtricitabine and tenofovir disoproxil fumarate) into a single tablet.

It recently demonstrated its efficacy in a 48-week phase II trial, during which it was able to deliver high virologic suppression and antiretroviral activity comparable to Atripla.

Dr Norbert Bischofberger, Gilead's executive vice-president of research and development and chief scientific officer, added that phase III data will be presented next year.

Earlier this month, the company applied for European regulatory approval of a new HIV regimen combining Truvada with TMC278, an investigational compound from Tibotec Pharmaceuticals.ADNFCR-8000103-ID-800065394-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.